A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study)
Purpose To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. Design Prospective, randomized, single-masked clinical trial. Methods Setting : Single center. Study Population : Thirty-three eyes of 33 pat...
Saved in:
Published in | American journal of ophthalmology Vol. 157; no. 5; pp. 960 - 970.e2 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.05.2014
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. Design Prospective, randomized, single-masked clinical trial. Methods Setting : Single center. Study Population : Thirty-three eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuity of 55 to 79 Early Treatment Diabetic Retinopathy Study letters at baseline, completing the 48-week study period. Intervention : Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 weeks as required; or macular laser therapy at baseline, repeated as required every 12 weeks. Exploratory Outcome Measures : Structural imaging studies included greatest linear dimension and area of foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography (Heidelberg Engineering GmbH, Heidelberg, Germany). Functional measures : Visual acuity, retinal sensitivity in the central 4 and 12 degrees on microperimetry, color contrast sensitivity protan and tritan thresholds, pattern and full-field electroretinogram amplitudes and implicit times, and multifocal electroretinogram amplitude distribution. These were reported at 12, 24, and 48 weeks. Results Ranibizumab-treated subjects gained 6.0 vs 0.9 letters lost for laser, demonstrated improved tritan and protan color contrast thresholds, and improved retinal sensitivity. Electrophysiologic function also improved after ranibizumab therapy. No safety issues were evident. Better retinal thickness reduction and structural improvement in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therapy than in the laser group. There was no evidence of progressive ischemia with ranibizumab therapy. Conclusions Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods. |
---|---|
AbstractList | Purpose To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. Design Prospective, randomized, single-masked clinical trial. Methods Setting: Single center.Study Population: Thirty-three eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuity of 55 to 79 Early Treatment Diabetic Retinopathy Study letters at baseline, completing the 48-week study period.Intervention: Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 weeks as required; or macular laser therapy at baseline, repeated as required every 12 weeks.Exploratory Outcome Measures: Structural imaging studies included greatest linear dimension and area of foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography (Heidelberg Engineering GmbH, Heidelberg, Germany).Functional measures: Visual acuity, retinal sensitivity in the central 4 and 12 degrees on microperimetry, color contrast sensitivity protan and tritan thresholds, pattern and full-field electroretinogram amplitudes and implicit times, and multifocal electroretinogram amplitude distribution. These were reported at 12, 24, and 48 weeks. Results Ranibizumab-treated subjects gained 6.0 vs 0.9 letters lost for laser, demonstrated improved tritan and protan color contrast thresholds, and improved retinal sensitivity. Electrophysiologic function also improved after ranibizumab therapy. No safety issues were evident. Better retinal thickness reduction and structural improvement in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therapy than in the laser group. There was no evidence of progressive ischemia with ranibizumab therapy. Conclusions Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods. To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. Prospective, randomized, single-masked clinical trial. Single center. Thirty-three eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuity of 55 to 79 Early Treatment Diabetic Retinopathy Study letters at baseline, completing the 48-week study period. Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 weeks as required; or macular laser therapy at baseline, repeated as required every 12 weeks. Exploratory Outcome Measures: Structural imaging studies included greatest linear dimension and area of foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography (Heidelberg Engineering GmbH, Heidelberg, Germany). Functional measures: Visual acuity, retinal sensitivity in the central 4 and 12 degrees on microperimetry, color contrast sensitivity protan and tritan thresholds, pattern and full-field electroretinogram amplitudes and implicit times, and multifocal electroretinogram amplitude distribution. These were reported at 12, 24, and 48 weeks. Ranibizumab-treated subjects gained 6.0 vs 0.9 letters lost for laser, demonstrated improved tritan and protan color contrast thresholds, and improved retinal sensitivity. Electrophysiologic function also improved after ranibizumab therapy. No safety issues were evident. Better retinal thickness reduction and structural improvement in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therapy than in the laser group. There was no evidence of progressive ischemia with ranibizumab therapy. Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods. Purpose To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. Design Prospective, randomized, single-masked clinical trial. Methods Setting : Single center. Study Population : Thirty-three eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuity of 55 to 79 Early Treatment Diabetic Retinopathy Study letters at baseline, completing the 48-week study period. Intervention : Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 weeks as required; or macular laser therapy at baseline, repeated as required every 12 weeks. Exploratory Outcome Measures : Structural imaging studies included greatest linear dimension and area of foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography (Heidelberg Engineering GmbH, Heidelberg, Germany). Functional measures : Visual acuity, retinal sensitivity in the central 4 and 12 degrees on microperimetry, color contrast sensitivity protan and tritan thresholds, pattern and full-field electroretinogram amplitudes and implicit times, and multifocal electroretinogram amplitude distribution. These were reported at 12, 24, and 48 weeks. Results Ranibizumab-treated subjects gained 6.0 vs 0.9 letters lost for laser, demonstrated improved tritan and protan color contrast thresholds, and improved retinal sensitivity. Electrophysiologic function also improved after ranibizumab therapy. No safety issues were evident. Better retinal thickness reduction and structural improvement in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therapy than in the laser group. There was no evidence of progressive ischemia with ranibizumab therapy. Conclusions Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods. To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. Prospective, randomized, single-masked clinical trial. Setting: Single center. Study Population: Thirty-three eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuity of 55 to 79 Early Treatment Diabetic Retinopathy Study letters at baseline, completing the 48-week study period. Intervention: Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 weeks as required; or macular laser therapy at baseline, repeated as required every 12 weeks. Exploratory Outcome Measures: Structural imaging studies included greatest linear dimension and area of foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography (Heidelberg Engineering GmbH, Heidelberg, Germany). Functional measures: Visual acuity, retinal sensitivity in the central 4 and 12 degrees on microperimetry, color contrast sensitivity protan and tritan thresholds, pattern and full-field electroretinogram amplitudes and implicit times, and multifocal electroretinogram amplitude distribution. These were reported at 12, 24, and 48 weeks. Ranibizumab-treated subjects gained 6.0 vs 0.9 letters lost for laser, demonstrated improved tritan and protan color contrast thresholds, and improved retinal sensitivity. Electrophysiologic function also improved after ranibizumab therapy. No safety issues were evident. Better retinal thickness reduction and structural improvement in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therapy than in the laser group. There was no evidence of progressive ischemia with ranibizumab therapy. Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods. PURPOSETo compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema. DESIGNProspective, randomized, single-masked clinical trial. METHODS SETTINGSingle center. STUDY POPULATIONThirty-three eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuity of 55 to 79 Early Treatment Diabetic Retinopathy Study letters at baseline, completing the 48-week study period. INTERVENTIONSubjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 weeks as required; or macular laser therapy at baseline, repeated as required every 12 weeks. Exploratory Outcome Measures: Structural imaging studies included greatest linear dimension and area of foveal avascular zone, perifoveal capillary dropout grade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography (Heidelberg Engineering GmbH, Heidelberg, Germany). Functional measures: Visual acuity, retinal sensitivity in the central 4 and 12 degrees on microperimetry, color contrast sensitivity protan and tritan thresholds, pattern and full-field electroretinogram amplitudes and implicit times, and multifocal electroretinogram amplitude distribution. These were reported at 12, 24, and 48 weeks. RESULTSRanibizumab-treated subjects gained 6.0 vs 0.9 letters lost for laser, demonstrated improved tritan and protan color contrast thresholds, and improved retinal sensitivity. Electrophysiologic function also improved after ranibizumab therapy. No safety issues were evident. Better retinal thickness reduction and structural improvement in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therapy than in the laser group. There was no evidence of progressive ischemia with ranibizumab therapy. CONCLUSIONSRanibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods. |
Author | Peto, Tunde Bainbridge, James W Patel, Praveen J Holder, Graham E Egan, Catherine A Neveu, Magella M Comyn, Oliver Xing, Wen Bunce, Catey V Sivaprasad, Sobha Hykin, Philip G |
Author_xml | – sequence: 1 fullname: Comyn, Oliver – sequence: 2 fullname: Sivaprasad, Sobha – sequence: 3 fullname: Peto, Tunde – sequence: 4 fullname: Neveu, Magella M – sequence: 5 fullname: Holder, Graham E – sequence: 6 fullname: Xing, Wen – sequence: 7 fullname: Bunce, Catey V – sequence: 8 fullname: Patel, Praveen J – sequence: 9 fullname: Egan, Catherine A – sequence: 10 fullname: Bainbridge, James W – sequence: 11 fullname: Hykin, Philip G |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24531025$$D View this record in MEDLINE/PubMed |
BookMark | eNp9klFrFDEUhYNU7Lb6A3yRgC_1YcYkk5nJIAjLdquFFcGuzyGT3MGMM5M2mRS2_8B_bYatCn3wKbnhOwdyzj1DJ5ObAKHXlOSU0Op9n6ve5YxQnhOWE9o8Qysq6iajoqEnaEUIYVlTNPwUnYXQp7Gqef0CnTJeFpSwcoV-rfE3NRk32gcweO-tGvDs8DoECAFfxUnP1k3pMUH4ZvZRz9Gncdt1oOeAXbfobWsf4qhafA8-xIB3KoDHdsKXVrUwW42_KB0H5fHWwKjwxfwD8O775vpyvd8m22gO716i550aArx6PM_R_mq733zOdl8_XW_Wu0yXhM1ZURlaqaqlheCEk4JpVRWdMJ1uK8OIMkaYFrpaMFGXZSMELaHoCOOaG9OY4hxdHG1vvbuLEGY52qBhGNQELgZJSyoYL0paJvTtE7R30acwjhRltKx4ouiR0t6F4KGTt96Oyh8kJXKpSfYy1SSXmiRhMtWUNG8enWM7gvmr-NNLAj4cAUhJ3FvwMmgLkwZjfcpdGmf_a__xiVoPdrJaDT_hAOHfL2RIAnmz7MmyJpSnWwqu-A3rRLgI |
CODEN | AJOPAA |
CitedBy_id | crossref_primary_10_1038_s41433_020_1054_2 crossref_primary_10_1371_journal_pone_0115797 crossref_primary_10_1007_s11428_015_0039_4 crossref_primary_10_4103_ijo_IJO_278_17 crossref_primary_10_1007_s10633_017_9601_2 crossref_primary_10_1159_000515148 crossref_primary_10_1007_s10792_021_01737_w crossref_primary_10_1016_j_preteyeres_2020_100907 crossref_primary_10_1159_000511380 crossref_primary_10_1007_s10633_015_9495_9 crossref_primary_10_3390_jcm13061534 crossref_primary_10_1038_s41433_020_1100_0 crossref_primary_10_1159_000505070 crossref_primary_10_1038_eye_2017_69 crossref_primary_10_1177_8755122515599552 crossref_primary_10_1155_2021_6654168 crossref_primary_10_3390_jcm10020357 crossref_primary_10_1177_11206721221146581 crossref_primary_10_1016_j_ajo_2016_02_004 crossref_primary_10_1093_ndt_gfac305 crossref_primary_10_1016_j_preteyeres_2015_05_002 crossref_primary_10_1007_s10792_021_01712_5 crossref_primary_10_1186_s12886_019_1200_4 crossref_primary_10_1038_s41433_021_01750_4 crossref_primary_10_1177_1932296819882719 crossref_primary_10_1080_14712598_2021_1928629 crossref_primary_10_1186_s40942_020_00265_6 crossref_primary_10_1371_journal_pone_0159553 crossref_primary_10_3390_ijms221910726 crossref_primary_10_1001_jamaophthalmol_2019_4636 crossref_primary_10_1186_s40942_023_00447_y crossref_primary_10_1016_j_sjopt_2018_10_003 crossref_primary_10_3390_jcm13082219 crossref_primary_10_1016_j_jcjo_2020_07_004 crossref_primary_10_1007_s00417_014_2897_7 crossref_primary_10_1007_s00417_018_4173_8 crossref_primary_10_4236_jbm_2024_122007 crossref_primary_10_2337_db20_1220 crossref_primary_10_1186_s12886_018_1006_9 crossref_primary_10_1080_07853890_2022_2064541 crossref_primary_10_1080_08820538_2017_1375125 crossref_primary_10_1016_j_visres_2016_09_019 crossref_primary_10_1002_14651858_CD007419_pub5 crossref_primary_10_1002_14651858_CD007419_pub6 crossref_primary_10_1111_aos_15673 crossref_primary_10_1002_14651858_CD007419_pub7 crossref_primary_10_1007_s00347_020_01244_w crossref_primary_10_3389_fphar_2022_876386 crossref_primary_10_1007_s00347_019_01015_2 crossref_primary_10_1007_s12325_023_02675_y crossref_primary_10_1007_s00417_020_04715_7 crossref_primary_10_1080_1744666X_2022_2037420 crossref_primary_10_3389_fmed_2023_1125062 crossref_primary_10_1001_jamaophthalmol_2021_0640 crossref_primary_10_1097_ICU_0000000000000424 crossref_primary_10_1167_tvst_9_11_2 crossref_primary_10_3389_fendo_2023_1096105 crossref_primary_10_1007_s10633_016_9531_4 crossref_primary_10_1097_ICU_0000000000001037 |
Cites_doi | 10.1097/IAE.0b013e3181d2f145 10.1038/sj.eye.6702014 10.1016/j.ajo.2007.07.011 10.1016/j.ophtha.2010.03.045 10.1016/j.ophtha.2008.10.016 10.1007/s10633-012-9353-y 10.1016/j.ophtha.2010.12.033 10.1016/j.ophtha.2011.12.039 10.1016/S0002-9394(14)74550-7 10.1016/j.ophtha.2010.02.031 10.1097/IAE.0b013e3181c96986 10.1038/eye.2009.207 10.1167/iovs.12-10895 10.1167/iovs.05-1141 10.1016/j.ophtha.2011.01.031 10.1007/s10633-008-9155-4 10.1186/1471-2415-8-15 10.1007/s10633-011-9296-8 10.1111/j.1755-3768.2008.01497.x 10.1076/ceyr.16.2.111.5094 10.1186/1471-2458-6-58 10.1016/S0002-9394(99)00227-5 |
ContentType | Journal Article |
Copyright | Elsevier Inc. 2014 Elsevier Inc. Copyright © 2014 Elsevier Inc. All rights reserved. Copyright Elsevier Limited May 2014 |
Copyright_xml | – notice: Elsevier Inc. – notice: 2014 Elsevier Inc. – notice: Copyright © 2014 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited May 2014 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. NAPCQ 7X8 |
DOI | 10.1016/j.ajo.2014.02.019 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-1891 |
EndPage | 970.e2 |
ExternalDocumentID | 3281573131 10_1016_j_ajo_2014_02_019 24531025 S0002939414000828 1_s2_0_S0002939414000828 |
Genre | Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States--US |
GeographicLocations_xml | – name: United States--US |
GrantInformation_xml | – fundername: Department of Health grantid: NIHR-RP-011-003 |
GroupedDBID | - 08R 0R 1 1- 1B1 1P 1~. 1~5 23M 3V. 4.4 457 4G. 53G 55 5GY 5RE 5VS 69O 6J9 7-5 71M 7RV 7X7 88E 8FI 8FJ 8G5 8P AABNK AACTN AAEDT AAHTB AAIAV AAIKJ AAKOC AALMO AALRI AALRV AAOAW AAPBV AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFLS ABFNM ABFRF ABLJU ABLVK ABMAC ABMZM ABOCM ABPEJ ABPIF ABPTK ABQIS ABUWG ABWYI ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACNCT ACRLP ADALY ADBBV ADEZE ADFRT AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKRA AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHMBA AI. AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AZFZN AZQEC BBAFP BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DWQXO EBS EFJIC EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FO FYUFA G- G-Q G8K GBLVA GJ GNUQQ GUQSH HVGLF HZ IHE IPNFZ J1W J5H K K-O KOM L7B LCYCR M M1P M2O M41 MO0 N4W N9A NAPCQ O-L O9- OAUVE OF- OPF OQ OZT P-8 P-9 P2P PADUT PC. PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSZ SV3 T5K UMP UNMZH UV1 VH1 WH7 WOW X X7M XPP Z5R ZA5 ZGI ZXP --- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1CY 1P~ 8P~ AAEDW ABCQX ABJNI ADMUD AHPSJ AXJTR EFLBG FYGXN HZ~ OQ~ ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
ID | FETCH-LOGICAL-c502t-36d16a6b138404032ca63f8dfcb6d20add8dbef782875598815e3f024c4dd9d3 |
IEDL.DBID | .~1 |
ISSN | 0002-9394 |
IngestDate | Fri Aug 16 11:27:37 EDT 2024 Fri Sep 20 00:52:14 EDT 2024 Thu Sep 26 18:05:27 EDT 2024 Sat Sep 28 08:23:01 EDT 2024 Fri Feb 23 02:29:08 EST 2024 Thu Aug 18 17:13:27 EDT 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | Copyright © 2014 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c502t-36d16a6b138404032ca63f8dfcb6d20add8dbef782875598815e3f024c4dd9d3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
ORCID | 0000-0001-6265-0381 |
PMID | 24531025 |
PQID | 1518121564 |
PQPubID | 41749 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1518243515 proquest_journals_1518121564 crossref_primary_10_1016_j_ajo_2014_02_019 pubmed_primary_24531025 elsevier_sciencedirect_doi_10_1016_j_ajo_2014_02_019 elsevier_clinicalkeyesjournals_1_s2_0_S0002939414000828 |
PublicationCentury | 2000 |
PublicationDate | 2014-05-01 |
PublicationDateYYYYMMDD | 2014-05-01 |
PublicationDate_xml | – month: 05 year: 2014 text: 2014-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Chicago |
PublicationTitle | American journal of ophthalmology |
PublicationTitleAlternate | Am J Ophthalmol |
PublicationYear | 2014 |
Publisher | Elsevier Inc Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
References | Marmor, Fulton, Holder (bib9) 2009; 118 Michaelides, Kaines, Hamilton (bib6) 2010; 117 Hood, Bach, Brigell (bib11) 2012; 124 Michaelides, Fraser-Bell, Hamilton (bib13) 2010; 30 Elman, Aiello, Beck (bib5) 2010; 117 Comyn, Heng, Ikeji (bib12) 2012; 53 Ciavarella, Moretti, Falsini, Porciatti (bib22) 1997; 16 Nakamura, Mitamura, Ogata, Arai, Takatsuna, Yamamoto (bib16) 2009; 24 Bunce, Wormald (bib2) 2006; 6 Bach, Brigell, Hawlina (bib10) 2013; 126 Okada, Yamamoto, Mizunoya, Hoshino, Arai, Takatsuna (bib14) 2006; 20 Unoki, Nishijima, Sakamoto (bib15) 2007; 144 Elman, Bressler, Qin (bib7) 2011; 118 Fong, Barton, Bresnick (bib19) 1999; 128 Karacorlu, Ozdemir, Senturk, Karacorlu, Uysal (bib18) 2010; 88 Vujosevic, Bottega, Casciano, Pilotto, Convento, Midena (bib17) 2010; 30 Mitchell, Bandello, Schmidt-Erfurth (bib3) 2011; 118 Vujosevic (bib8) 2006; 47 Prager, Garcia, Mincher, Mishra, Chu (bib21) 1990; 109 Klein, Knudtson, Lee, Gangnon, Klein (bib1) 2009; 116 Nguyen, Brown, Marcus (bib4) 2012; 119 Wong, Khan, Adewoyin, Sivaprasad, Arden, Chong (bib20) 2008; 8 Vujosevic (10.1016/j.ajo.2014.02.019_bib8) 2006; 47 Marmor (10.1016/j.ajo.2014.02.019_bib9) 2009; 118 Nakamura (10.1016/j.ajo.2014.02.019_bib16) 2009; 24 Bunce (10.1016/j.ajo.2014.02.019_bib2) 2006; 6 Mitchell (10.1016/j.ajo.2014.02.019_bib3) 2011; 118 Prager (10.1016/j.ajo.2014.02.019_bib21) 1990; 109 Michaelides (10.1016/j.ajo.2014.02.019_bib13) 2010; 30 Fong (10.1016/j.ajo.2014.02.019_bib19) 1999; 128 Nguyen (10.1016/j.ajo.2014.02.019_bib4) 2012; 119 Karacorlu (10.1016/j.ajo.2014.02.019_bib18) 2010; 88 Hood (10.1016/j.ajo.2014.02.019_bib11) 2012; 124 Unoki (10.1016/j.ajo.2014.02.019_bib15) 2007; 144 Michaelides (10.1016/j.ajo.2014.02.019_bib6) 2010; 117 Okada (10.1016/j.ajo.2014.02.019_bib14) 2006; 20 Vujosevic (10.1016/j.ajo.2014.02.019_bib17) 2010; 30 Elman (10.1016/j.ajo.2014.02.019_bib5) 2010; 117 Comyn (10.1016/j.ajo.2014.02.019_bib12) 2012; 53 Bach (10.1016/j.ajo.2014.02.019_bib10) 2013; 126 Klein (10.1016/j.ajo.2014.02.019_bib1) 2009; 116 Ciavarella (10.1016/j.ajo.2014.02.019_bib22) 1997; 16 Elman (10.1016/j.ajo.2014.02.019_bib7) 2011; 118 Wong (10.1016/j.ajo.2014.02.019_bib20) 2008; 8 |
References_xml | – volume: 128 start-page: 612 year: 1999 end-page: 617 ident: bib19 article-title: Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study report no. 15 publication-title: Am J Ophthalmol contributor: fullname: Bresnick – volume: 16 start-page: 111 year: 1997 end-page: 115 ident: bib22 article-title: The pattern electroretinogram (PERG) after laser treatment of the peripheral or central retina publication-title: Curr Eye Res contributor: fullname: Porciatti – volume: 126 start-page: 1 year: 2013 end-page: 7 ident: bib10 article-title: ISCEV standard for clinical pattern electroretinography (PERG): 2012 update publication-title: Doc Ophthalmol contributor: fullname: Hawlina – volume: 88 start-page: 558 year: 2010 end-page: 563 ident: bib18 article-title: Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema publication-title: Acta Ophthalmol contributor: fullname: Uysal – volume: 118 start-page: 609 year: 2011 end-page: 614 ident: bib7 article-title: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema publication-title: Ophthalmology contributor: fullname: Qin – volume: 118 start-page: 69 year: 2009 end-page: 77 ident: bib9 article-title: ISCEV standard for full-field clinical electroretinography (2008 update) publication-title: Doc Ophthalmol contributor: fullname: Holder – volume: 6 start-page: 58 year: 2006 ident: bib2 article-title: Leading causes of certification for blindness and partial sight in England & Wales publication-title: BMC Public Health contributor: fullname: Wormald – volume: 20 start-page: 805 year: 2006 end-page: 809 ident: bib14 article-title: Correlation of retinal sensitivity measured with fundus-related microperimetry to visual acuity and retinal thickness in eyes with diabetic macular edema publication-title: Eye (Lond) contributor: fullname: Takatsuna – volume: 144 start-page: 755 year: 2007 end-page: 760.e1 ident: bib15 article-title: Retinal sensitivity loss and structural disturbance in areas of capillary nonperfusion of eyes with diabetic retinopathy publication-title: Am J Ophthalmol contributor: fullname: Sakamoto – volume: 30 start-page: 781 year: 2010 end-page: 786 ident: bib13 article-title: Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): report 1 publication-title: Retina contributor: fullname: Hamilton – volume: 24 start-page: 784 year: 2009 end-page: 788 ident: bib16 article-title: Functional and morphological changes of macula after subthreshold micropulse diode laser photocoagulation for diabetic macular oedema publication-title: Eye (Lond) contributor: fullname: Yamamoto – volume: 119 start-page: 789 year: 2012 end-page: 801 ident: bib4 article-title: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE publication-title: Ophthalmology contributor: fullname: Marcus – volume: 30 start-page: 908 year: 2010 end-page: 916 ident: bib17 article-title: Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation publication-title: Retina contributor: fullname: Midena – volume: 117 start-page: 1078 year: 2010 end-page: 1086.e2 ident: bib6 article-title: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2 publication-title: Ophthalmology contributor: fullname: Hamilton – volume: 124 start-page: 1 year: 2012 end-page: 13 ident: bib11 article-title: ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition) publication-title: Doc Ophthalmol contributor: fullname: Brigell – volume: 47 start-page: 3044 year: 2006 end-page: 3051 ident: bib8 article-title: Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Vujosevic – volume: 53 start-page: 7754 year: 2012 end-page: 7759 ident: bib12 article-title: Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Ikeji – volume: 109 start-page: 279 year: 1990 end-page: 284 ident: bib21 article-title: The pattern electroretinogram in diabetes publication-title: Am J Ophthalmol contributor: fullname: Chu – volume: 117 start-page: 1064 year: 2010 end-page: 1077.e35 ident: bib5 article-title: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema publication-title: Ophthalmology contributor: fullname: Beck – volume: 116 start-page: 497 year: 2009 end-page: 503 ident: bib1 article-title: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes publication-title: Ophthalmology contributor: fullname: Klein – volume: 118 start-page: 615 year: 2011 end-page: 625 ident: bib3 article-title: The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema publication-title: Ophthalmology contributor: fullname: Schmidt-Erfurth – volume: 8 start-page: 15 year: 2008 ident: bib20 article-title: The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study publication-title: BMC Ophthalmol contributor: fullname: Chong – volume: 30 start-page: 781 issue: 5 year: 2010 ident: 10.1016/j.ajo.2014.02.019_bib13 article-title: Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): report 1 publication-title: Retina doi: 10.1097/IAE.0b013e3181d2f145 contributor: fullname: Michaelides – volume: 20 start-page: 805 issue: 7 year: 2006 ident: 10.1016/j.ajo.2014.02.019_bib14 article-title: Correlation of retinal sensitivity measured with fundus-related microperimetry to visual acuity and retinal thickness in eyes with diabetic macular edema publication-title: Eye (Lond) doi: 10.1038/sj.eye.6702014 contributor: fullname: Okada – volume: 144 start-page: 755 issue: 5 year: 2007 ident: 10.1016/j.ajo.2014.02.019_bib15 article-title: Retinal sensitivity loss and structural disturbance in areas of capillary nonperfusion of eyes with diabetic retinopathy publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.07.011 contributor: fullname: Unoki – volume: 117 start-page: 1078 issue: 6 year: 2010 ident: 10.1016/j.ajo.2014.02.019_bib6 article-title: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.03.045 contributor: fullname: Michaelides – volume: 116 start-page: 497 issue: 3 year: 2009 ident: 10.1016/j.ajo.2014.02.019_bib1 article-title: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.10.016 contributor: fullname: Klein – volume: 126 start-page: 1 issue: 1 year: 2013 ident: 10.1016/j.ajo.2014.02.019_bib10 article-title: ISCEV standard for clinical pattern electroretinography (PERG): 2012 update publication-title: Doc Ophthalmol doi: 10.1007/s10633-012-9353-y contributor: fullname: Bach – volume: 118 start-page: 609 issue: 4 year: 2011 ident: 10.1016/j.ajo.2014.02.019_bib7 article-title: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.12.033 contributor: fullname: Elman – volume: 119 start-page: 789 issue: 4 year: 2012 ident: 10.1016/j.ajo.2014.02.019_bib4 article-title: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.12.039 contributor: fullname: Nguyen – volume: 109 start-page: 279 issue: 3 year: 1990 ident: 10.1016/j.ajo.2014.02.019_bib21 article-title: The pattern electroretinogram in diabetes publication-title: Am J Ophthalmol doi: 10.1016/S0002-9394(14)74550-7 contributor: fullname: Prager – volume: 117 start-page: 1064 issue: 6 year: 2010 ident: 10.1016/j.ajo.2014.02.019_bib5 article-title: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.02.031 contributor: fullname: Elman – volume: 30 start-page: 908 issue: 6 year: 2010 ident: 10.1016/j.ajo.2014.02.019_bib17 article-title: Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation publication-title: Retina doi: 10.1097/IAE.0b013e3181c96986 contributor: fullname: Vujosevic – volume: 24 start-page: 784 issue: 5 year: 2009 ident: 10.1016/j.ajo.2014.02.019_bib16 article-title: Functional and morphological changes of macula after subthreshold micropulse diode laser photocoagulation for diabetic macular oedema publication-title: Eye (Lond) doi: 10.1038/eye.2009.207 contributor: fullname: Nakamura – volume: 53 start-page: 7754 issue: 12 year: 2012 ident: 10.1016/j.ajo.2014.02.019_bib12 article-title: Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.12-10895 contributor: fullname: Comyn – volume: 47 start-page: 3044 issue: 7 year: 2006 ident: 10.1016/j.ajo.2014.02.019_bib8 article-title: Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.05-1141 contributor: fullname: Vujosevic – volume: 118 start-page: 615 issue: 4 year: 2011 ident: 10.1016/j.ajo.2014.02.019_bib3 article-title: The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.01.031 contributor: fullname: Mitchell – volume: 118 start-page: 69 issue: 1 year: 2009 ident: 10.1016/j.ajo.2014.02.019_bib9 article-title: ISCEV standard for full-field clinical electroretinography (2008 update) publication-title: Doc Ophthalmol doi: 10.1007/s10633-008-9155-4 contributor: fullname: Marmor – volume: 8 start-page: 15 year: 2008 ident: 10.1016/j.ajo.2014.02.019_bib20 article-title: The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study publication-title: BMC Ophthalmol doi: 10.1186/1471-2415-8-15 contributor: fullname: Wong – volume: 124 start-page: 1 issue: 1 year: 2012 ident: 10.1016/j.ajo.2014.02.019_bib11 article-title: ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition) publication-title: Doc Ophthalmol doi: 10.1007/s10633-011-9296-8 contributor: fullname: Hood – volume: 88 start-page: 558 issue: 5 year: 2010 ident: 10.1016/j.ajo.2014.02.019_bib18 article-title: Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.2008.01497.x contributor: fullname: Karacorlu – volume: 16 start-page: 111 issue: 2 year: 1997 ident: 10.1016/j.ajo.2014.02.019_bib22 article-title: The pattern electroretinogram (PERG) after laser treatment of the peripheral or central retina publication-title: Curr Eye Res doi: 10.1076/ceyr.16.2.111.5094 contributor: fullname: Ciavarella – volume: 6 start-page: 58 issue: 1 year: 2006 ident: 10.1016/j.ajo.2014.02.019_bib2 article-title: Leading causes of certification for blindness and partial sight in England & Wales publication-title: BMC Public Health doi: 10.1186/1471-2458-6-58 contributor: fullname: Bunce – volume: 128 start-page: 612 issue: 5 year: 1999 ident: 10.1016/j.ajo.2014.02.019_bib19 article-title: Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study report no. 15 publication-title: Am J Ophthalmol doi: 10.1016/S0002-9394(99)00227-5 contributor: fullname: Fong |
SSID | ssj0006747 |
Score | 2.41616 |
Snippet | Purpose To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema.... To compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema.... PURPOSETo compare the functional and structural effects of ranibizumab versus macular laser therapy in patients with center-involving diabetic macular edema.... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 960 |
SubjectTerms | Aged Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Cataracts Clinical medicine Clinical trials Color Perception - physiology Contrast Sensitivity - physiology Diabetes Diabetic retinopathy Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Diabetic Retinopathy - surgery Diabetic Retinopathy - therapy Drug therapy Electroretinography Female Fluorescein Angiography Heart attacks Humans Intravitreal Injections Ischemia Laser Coagulation Macular degeneration Macular Edema - drug therapy Macular Edema - physiopathology Macular Edema - surgery Macular Edema - therapy Male Medical imaging Middle Aged Ophthalmology Pharmaceutical industry Ranibizumab Retina - physiopathology Retreatment Tomography, Optical Coherence Vascular endothelial growth factor Visual Acuity - physiology Visual Field Tests |
Title | A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study) |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0002939414000828 https://dx.doi.org/10.1016/j.ajo.2014.02.019 https://www.ncbi.nlm.nih.gov/pubmed/24531025 https://www.proquest.com/docview/1518121564/abstract/ https://search.proquest.com/docview/1518243515 |
Volume | 157 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhgdJLadOX2yRMoYe24MYPSfYel80umzabQ7uB3IRkyeDA2iHePTSH3POvO2PZG0ofhx5ty8jWjGY-Wd98Zux94qQu49iEUtg05LjUCXNdpGGWcz6K0jLinZTS4lzOL_iXS3G5wyZDLQzRKvvY72N6F637M8f9aB5fVxXV-EaYq0YclwidEBtVsGMyQp_-fPdA85AZzwYITK2Hnc2O46WvqP4v5p1sJ4nt_Dk3_Q17djlo9pQ96cEjjP3zPWM7rt5njxb99vhzdj-Gb7q2zaq6dRaW5FuwbsBv7MIMU5j_8gfYCL53yrGkugFewriFpqT7K1PdblbaADE2Ni2cYaK7gaoGz56pCljojr0KU-tWGj4ghoSzi8npyXg5BSIm_vj4gi1n0-VkHvb_WggLESXrMJU2llqaOMUVH4_SpNAyLXNbFkbaJMIomFvjyoz08UnTPY-FQ0smvODWjmz6ku3WTe1eMxBSa4GrblGUgiN-MNbQb2UQKcSOF8YE7NMwyOraK2qogWp2pdAiiiyiokShRQKWDWZQQ6koBjfX9jOtVbFqsaX6zRsCxrd3_uJQCnPFvzo8GIytHvoQhINIVidg77aXcR7S5oquXbPxbRLEnrEI2CvvJNvXSzhGOgSXb_7vmd6yx3TkaZYHbBfdwx0iFFqbo87Xj9je-PTr_PwnlzcElg |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB4tXQm4IN4EFjASB0CKNk5sJz1WpVXLtj1AVtqbZceOlJWarEh72P0H-68Zx0kR4nHgGtty4hnPfM7MfAZ4H1uhSkp1KLhJQoZHnTBTRRKmGWPjKCkj1lEprTdicc6-XPCLI5gOtTAurbK3_d6md9a6f3Lar-bpVVW5Gt8IfdWY4RGhI2K7A8eMp5SN4HiyPFtsDgZZpCwdULAbMAQ3uzQvdelKACnrmDsd386f3dPf4GfnhuYP4UGPH8nEv-IjOLL1Y7i77iPkT-B2Qr6q2jTb6sYakjv1IruG-NgumaMX8z__CHYi3zryWEe8QTyLcUua0o2vdHWz3ypNXNLGviUr9HXfSVUTn0BTFWStugRWMjN2q8gHhJFkdT5dfp7kM-JyE68_PoV8Psuni7C_biEseBTvwkQYKpTQNMFDH4uSuFAiKTNTFlqYOEJDmBlty9RR5Dta94xyi8KMWcGMGZvkGYzqprYvgHChFMeDNy9KzhBCaKPdzTIIFqhlhdYBfBoWWV55Ug05ZJtdSpSIdBKRUSxRIgGkgxjkUC2K9s22_WZrJZUt9pS_KUQA7DDyF52S6C7-NeHJIGz5cw7uoJBj1gng3aEZt6KLr6jaNnvfJ0b4SXkAz72SHD4vZmjsEF--_L93egv3Fvl6JVfLzdkruO9afNblCYxQVexrREY7_abX_B-TQgdM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Randomized+Trial+to+Assess+Functional+and+Structural+Effects+of+Ranibizumab+versus+Laser+in+Diabetic+Macular+Edema+%28the+LUCIDATE+Study%29&rft.jtitle=American+journal+of+ophthalmology&rft.au=Comyn%2C+Oliver&rft.au=Sivaprasad%2C+Sobha&rft.au=Peto%2C+Tunde&rft.au=Neveu%2C+Magella+M.&rft.date=2014-05-01&rft.issn=0002-9394&rft.volume=157&rft.issue=5&rft.spage=960&rft.epage=970.e2&rft_id=info:doi/10.1016%2Fj.ajo.2014.02.019&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ajo_2014_02_019 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029394%2FS0002939413X00169%2Fcov150h.gif |